chartexchange

BCAB
BIOATLA INC
stockOTC

EODNov 16, 2026
1.99USD+27.564%(+0.43)9,562
Loading…
Loading…
Healthcare
Biotechnology
HQ
San Diego, CA, USA
Previous Close
$1.56
Beta
0.04
52-Week High
$71.50 2025-11-19
52-Week Low
$1.07 2026-09-01
SMA 50
$1.62
SMA 200
$4.30
Avg. Vol 10D
7,113
Avg. Vol 30D
6,557
Avg. Vol 90D
44,652
Relative Vol
1.46
1.38M
277
Apr 6, 2026 · 1-for-50 (reverse)
BCAB Profile

bioatla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. the culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our conditionally active biologics (cab) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. this improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. bioatla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.

BCAB Performance
PeriodPriceDateChangeBeta
1W1.832026-11-10+8.74%-7.921
1M1.362026-10-16+46.32%-1.082
3M3.062026-08-17-34.97%-0.215
6M3.922026-05-18-49.23%0.481
1Y51.002025-11-17-96.10%0.038
2Y75.502024-11-18-97.36%—
5Y1,414.002021-11-17-99.86%1.682
BCAB Stock Summary

BIOATLA INC (OTC:BCAB) stock price today is $1.99, and today's volume is 9,562. BCAB is up 27.564% today. The 30 day average volume is 6,557. BCAB market cap is $3.32M with 1.67M shares outstanding.